Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111957 | 0.82 | CES2 (0.36) | ALDH1A1 | |
| SCHEMBL5506924 | 0.82 | ALDH1A1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL31414602 | 0.82 | CA1 (0.40) | MAPTCA3CA6CA5ACA9 | |
| SCHEMBL19000144 | 0.82 | CA1 (0.40) | MAPTCA3CA6CA5ACA9 | |
| SCHEMBL18341100 | 0.82 | TSHR (0.40) | ALDH1A1MEN1MAPTKMT2ACA9 | |
| SCHEMBL3670713 | 0.82 | POLB (0.46) | ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL113475 | 0.77 | — | — | |
| SCHEMBL102976 | 0.77 | ERN1 (0.39) | ALDH1A1CA3CA6CA5ACA9 | |
| SCHEMBL2777071 | 0.77 | TNF (0.38) | ALDH1A1CA9 | |
| SCHEMBL657099 | 0.77 | ALDH1A1 (0.42) | ALDH1A1MAPTCA6CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158385-A1 | NOVEL COMPOUNDS | Cerevance, Inc. | 2024-05-16 | — | — | US | disclosed |
| CN-111344287-B | Novel substituted biaryl compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors | 默沙东有限责任公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-116981665-A | Novel compounds | 思瑞万斯公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| EP-3710444-B1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2576540-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010025451-A2 | 5,8-DIFLUORO-4-(2-(4-(HETEROARYLOXY)-PHENYL)ETHYLAMINO)QUINAZOLINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2010-03-04 | — | — | WO | disclosed |
| US-7208559-B2 | Ethylened polymer and molded object obtained therefrom | MITSUI CHEMICALS, INC. (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20060135712-A1 | Ethylened polymer and molded object obtained therefrom | MITSUI CHEMICALS, INC. (JP) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CDK1, CSNK1A1, CSNK1G1 | ALDH1A1 4307/4885MEN1 837/4885MAPT 286/4885 |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | ALDH1A1 1807/4885MEN1 2755/4885MAPT 1590/4885 |
| US-20240158385-A1 | NOVEL COMPOUNDS | KCNK3, KCNA4, KCNK13 | ALDH1A1 2143/4885MEN1 1930/4885MAPT 4204/4885 |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | ALDH1A1 560/4885MEN1 3126/4885MAPT 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.